CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 88 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00284089
NCT00284089Phase 2Completed
CompareCT.gov

Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Novartis·interventional·Posted Jan 31, 2006·Updated Feb 24, 2011

In Brief

A Phase 2 clinical trial evaluating Ranibizumab for Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD). Completed, enrolled 88 participants across 1 site.

Detailed Summary

Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2006
Enrollment StartApr 1, 2005
Primary CompletionMar 1, 2007
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.4 years ago

Interventions

Ranibizumabdrug

Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.